Healthcare Industry News: HSMN NewsFeed

Devices Oncology

 News Release - October 31, 2010

IBA Introduces Proteus ONE*, a Smaller, More Cost-Effective Proton Therapy System

Proteus ONE™* is a new single-room system that substantially reduces cost, minimizes the space and shortens the installation time required to build a Proton Therapy center.

SAN DIEGO--(Healthcare Sales & Marketing Network)-- A smaller, more efficient and cost-effective Proton Therapy system from IBA Particle Therapy will soon be available for cancer treatment centers. This single-room system is roughly one-third the size of the current gantry configuration and offers a smaller cyclotron, a shorter proton-beam route from the cyclotron to the treatment room, and a more compact gantry.

Premiering for the first time at the 52nd annual meeting of the American Society for Radiation Oncology held in San Diego, Proteus ONE will be a more affordable option for many cancer centers. IBA’s latest innovation offers a considerably smaller treatment room that will help reduce costs substantially, minimize the space and shorten the installation time required to build a Proton Therapy center. In addition, the Proteus ONE offers integrated 3-D Cone Beam CT imaging that rotates around a patient, capturing detailed tumor images.

The Proteus ONE is an even smaller, more affordable Proton Therapy treatment room for cancer patients than the Proteus Nano®, a two-room treatment solution introduced by IBA Particle Therapy in the fall of 2009. A significant advantage to the Proteus ONE development is its ability to leverage existing, proven IBA technology, including the Pencil Beam Scanning proton delivery method and advanced treatment control system.

“Proteus ONE extends the range of possibilities IBA systems offer to the health community, reducing the cost of Particle Therapy,” said IBA Founder Yves Jongen. “While Proteus® 235 remains the most advanced and adaptable Proton Therapy system on the market, Proteus ONE will allow more patients to benefit from IBA technology.”

IBA engineers and designers have spent more than a year devising Proteus ONE.

The first treatment room is scheduled to open at a planned Proton Therapy center in Europe in less than four years.


Proton Therapy is considered the most advanced and targeted cancer treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and, even better, spare healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long-term complications, thereby improving outcomes and quality of life for patients. Unfortunately, very few patients can yet benefit from this type of treatment around the world.


IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.

(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).


*Subject to review by Competent Authorities (FDA, European Notified Bodies, et al.) before being put on the market.

Source: IBA Particle Therapy

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.